An estimated 50 million people worldwide live with hepatitis C virus (HCV) infection, a leading cause of chronic liver disease, cirrhosis, and liver cancer. While highly effective antiviral treatments exist, access remains a significant barrier globally, and these therapies don’t prevent reinfection. Now, a new approach utilizing nanoparticle technology offers a promising path toward a durable vaccine, addressing a decades-long challenge in the field of virology.
The difficulty in developing an HCV vaccine stems from the virus’s ability to evade the immune system. This evasion is largely due to two proteins, E1 and E2, which coat the virus’s surface. These proteins have historically been unstable and demanding to reproduce in a form suitable for triggering a protective immune response. Researchers have long sought a way to create a stable version of the E1E2 glycoprotein complex, a crucial step toward a viable vaccine.
Stabilizing the Viral Surface for Vaccine Development
Scientists at Scripps Research have made a breakthrough in stabilizing the HCV E1E2 complex, paving the way for a nanoparticle-based vaccine candidate. Their findings, published as an article-in-press on February 11, 2026, in Nature Communications, detail the engineering of a native-like, stabilized version of the complex. The team employed a technology called self-assembling protein nanoparticles (SApNPs), which organizes multiple copies of the proteins into clusters resembling the virus itself, enhancing recognition by the immune system. The study outlines the process and initial results of this innovative approach.
“Our lab focuses on all the major virus families, including those with surface proteins that are too unstable to use in traditional vaccines,” explained senior author Jiang Zhu, a professor at Scripps Research. “For HCV, the central problem for decades has been that the two surface proteins, E1 and E2, fall apart or misassemble when removed from the virus. In this study, we were able to stabilize the native E1–E2 interface and generate a soluble complex that faithfully mimics the viral surface.”
Overcoming Decades of Challenges
The E1 and E2 proteins function as heterodimers, tightly linked pairs that shield the virus and facilitate entry into human cells. Creating a stable, soluble E1E2 complex has been a major hurdle for over two decades. Without it, vaccines struggle to effectively train the immune system to recognize the true structure of the virus. The Scripps Research team tackled this challenge from an engineering perspective, designing a molecular scaffold to hold E1 and E2 together in their natural orientation.
Researchers reinforced key contact points that typically destabilize the proteins outside of the viral membrane. They likewise trimmed flexible regions that interfered with proper folding and added protein scaffolds to lock the pair into the correct alignment. Electron microscopy confirmed that the engineered proteins maintained their native structure. “Normally, these glycoproteins are extremely fragile,” Zhu added. “In the redesigned version, they became rock solid, while keeping the same shape the immune system requires to recognize them. That stability is essential given that antibodies that neutralize HCV recognize a very specific arrangement of E1 and E2. If that interface isn’t preserved, the vaccine won’t present the right target.”
Nanoparticle Technology Amplifies Immune Response
The stabilized proteins were then displayed on Zhu’s SApNP technology, with sixty copies clustered together on each particle. This mimics the natural presentation of viruses and amplifies the body’s immune response. Initial testing in animal models showed that the HCV nanoparticle vaccine candidates triggered immune responses directed at the viral surface. “The soluble, stabilized E1E2 complex serves as the foundation for this multivalent display, potentially enabling a vaccine format that was previously not feasible,” Zhu stated.
Zhu’s lab has a history of developing nanoparticle-based platforms for various vaccine targets, including HIV, influenza, and filoviruses like Ebola, Sudan, and Marburg. This rational, structure-based design approach involves detailed analysis of viral surface proteins, engineering stable versions, and mounting them on virus-like particles to stimulate a strong antibody response. “HCV was one of the most challenging because it’s a very difficult vaccine target,” Zhu explained. “Our rational design approach allowed us to first identify why the virus’ surface glycoproteins are so unstable, and then engineer solutions to overcome those challenges. Solving the soluble E1E2 problem removes a major bottleneck that has limited structure-based HCV vaccine design for decades.”
The stabilized E1 and E2 proteins also hold promise beyond vaccine development, potentially serving as a template for researchers creating both vaccines and antibody-based therapies. This breakthrough also opens new avenues for structural studies and the discovery of therapeutic antibodies.
The team is now focused on refining the HCV vaccine candidates to enhance immune responses and evaluating their protective capabilities in further studies. Zhu is also exploring strategies to improve the overall effectiveness of these vaccines. “Over the last seven to eight years, I’ve been focused on solving protein designs for the major virus families,” he said. “Now, I’m also exploring strategies to further enhance the effectiveness of these vaccines, with additional research forthcoming.”
Disclaimer: This article provides information about medical research and is not intended to provide medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The development of a hepatitis C vaccine represents a significant step forward in global health. Researchers will continue to refine these candidates and assess their efficacy in clinical trials. Further updates on this research will be published as they develop into available.
Have thoughts on this story? Share your comments below.
